Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

ReDO_DB: the repurposing drugs in oncology database.

Pantziarka P, Verbaanderd C, Sukhatme V, Rica Capistrano I, Crispino S, Gyawali B, Rooman I, Van Nuffel AM, Meheus L, Sukhatme VP, Bouche G.

Ecancermedicalscience. 2018 Dec 6;12:886. doi: 10.3332/ecancer.2018.886. eCollection 2018.

2.

Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.

Pantziarka P, Sukhatme V, Crispino S, Bouche G, Meheus L, Sukhatme VP.

Ecancermedicalscience. 2018 Apr 11;12:824. doi: 10.3332/ecancer.2018.824. eCollection 2018.

3.

Perioperative therapies - Enhancing the impact of cancer surgery with repurposed drugs.

Pantziarka P, Bouche G, Sullivan R, Ilbawi AM, Dare AJ, Meheus L.

Eur J Surg Oncol. 2017 Nov;43(11):1985-1988. doi: 10.1016/j.ejso.2017.08.010. Epub 2017 Sep 7.

PMID:
28928011
4.

Repurposing Drugs in Oncology: Next Steps.

Verbaanderd C, Meheus L, Huys I, Pantziarka P.

Trends Cancer. 2017 Aug;3(8):543-546. doi: 10.1016/j.trecan.2017.06.007. Epub 2017 Jul 12.

PMID:
28780930
5.

Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent.

Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP.

Ecancermedicalscience. 2016 Oct 12;10:680. eCollection 2016.

6.

Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer.

Chandra D, Jahangir A, Cornelis F, Rombauts K, Meheus L, Jorcyk CL, Gravekamp C.

Oncoimmunology. 2015 May 29;5(1):e1049802. eCollection 2016.

7.

Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.

Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP.

Ecancermedicalscience. 2016 Jan 11;10:610. doi: 10.3332/ecancer.2016.610. eCollection 2016.

8.

Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.

Sukhatme V, Bouche G, Meheus L, Sukhatme VP, Pantziarka P.

Ecancermedicalscience. 2015 Aug 27;9:568. doi: 10.3332/ecancer.2015.568. eCollection 2015.

9.

Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.

Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP.

Ecancermedicalscience. 2015 Apr 15;9:521. doi: 10.3332/ecancer.2015.521. eCollection 2015.

10.

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G.

Ecancermedicalscience. 2015 Feb 24;9:513. doi: 10.3332/ecancer.2015.513. eCollection 2015.

11.

Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP.

Future Oncol. 2015;11(2):181-4. doi: 10.2217/fon.14.244. No abstract available.

12.

Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent.

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP.

Ecancermedicalscience. 2014 Nov 26;8:485. doi: 10.3332/ecancer.2014.485. eCollection 2014.

13.

Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent.

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP.

Ecancermedicalscience. 2014 Jul 10;8:443. doi: 10.3332/ecancer.2014.443. eCollection 2014.

14.

The Repurposing Drugs in Oncology (ReDO) Project.

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P.

Ecancermedicalscience. 2014 Jul 10;8:442. doi: 10.3332/ecancer.2014.442. eCollection 2014.

15.

Inconsistencies and questionable reliability of the publication "immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF" by Yamamoto et al.

Ugarte A, Bouche G, Meheus L.

Cancer Immunol Immunother. 2014 Dec;63(12):1347-8. doi: 10.1007/s00262-014-1587-y. Epub 2014 Jul 24. No abstract available.

16.

GENimmune NV.

Maertens G, Meheus L, Shapiro F, van Broekhoven A, Buyens G.

Per Med. 2008 Mar;5(2):183-188. doi: 10.2217/17410541.5.2.183.

PMID:
29783352
17.

Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections.

Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, Krakover J, Murthy S, Huang M, Power S, Babé L, Dahlberg C, McKinney D, Sette A, Southwood S, Philip R, Newman MJ, Meheus L.

J Virol. 2008 Jan;82(1):435-50. Epub 2007 Oct 17.

18.
19.

Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus.

Hoffman IE, Peene I, Cebecauer L, Isenberg D, Huizinga TW, Union A, Meheus L, De Bosschere K, Hulstaert F, Veys EM, De Keyser F.

Ann Rheum Dis. 2005 Feb;64(2):330-2. No abstract available.

20.

Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus.

Gordon P, Khamashta MA, Rosenthal E, Simpson JM, Sharland G, Brucato A, Franceschini F, De Bosschere K, Meheus L, Meroni PL, Hughes GR, Buyon J.

J Rheumatol. 2004 Dec;31(12):2480-7.

PMID:
15570655
21.

Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations.

De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Boullart L, Serre G, Veys EM, De Keyser F.

Ann Rheum Dis. 2004 Dec;63(12):1587-93.

22.

Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoantibodies in connective tissue disorders.

Pottel H, Wiik A, Locht H, Gordon T, Roberts-Thomson P, Abraham D, Goossens K, Dobbels C, De Bosschere K, Hulstaert F, Meheus L.

Clin Exp Rheumatol. 2004 Sep-Oct;22(5):579-88.

PMID:
15485011
23.

Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis.

Hoffman IE, Peene I, Pottel H, Union A, Hulstaert F, Meheus L, Lebeer K, De Clercq L, Schatteman L, Poriau S, Mielants H, Veys EM, De Keyser F.

Clin Chem. 2005 Jan;51(1):261-3. Epub 2004 Sep 23. No abstract available.

24.

Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus.

Hoffman IE, Peene I, Meheus L, Huizinga TW, Cebecauer L, Isenberg D, De Bosschere K, Hulstaert F, Veys EM, De Keyser F.

Ann Rheum Dis. 2004 Sep;63(9):1155-8.

26.

Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease.

Peene I, Meheus L, De Keyser S, Humbel R, Veys EM, De Keyser F.

Ann Rheum Dis. 2002 Oct;61(10):929-33.

27.

Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay.

Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, Pottel H, Serre G, De Keyser F.

Arthritis Rheum. 2002 May;46(5):1185-95.

28.
29.
30.

Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies.

Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, Veys EM, De Keyser F.

Arthritis Rheum. 2001 Oct;44(10):2255-62.

31.

Autoantibodies within families of patients with systemic lupus erythematosus are not directed against the same nuclear antigens.

van der Linden MW, Westendorp RG, Zidane M, Meheus L, Huizinga TW.

J Rheumatol. 2001 Feb;28(2):284-7.

PMID:
11246662
33.
34.

Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders.

Meheus L, van Venrooij WJ, Wiik A, Charles PJ, Tzioufas AG, Meyer O, Steiner G, Gianola D, Bombardieri S, Union A, De Keyser S, Veys E, De Keyser F.

Clin Exp Rheumatol. 1999 Mar-Apr;17(2):205-14.

PMID:
10342047
35.

Cholangiocyte-specific rat liver proteins identified by establishment of a two-dimensional gel protein database.

Tietz P, de Groen PC, Anderson NL, Sims C, Esquer-Blasco R, Meheus L, Raymackers J, Dauwe M, LaRusso NF.

Electrophoresis. 1998 Dec;19(18):3207-12.

PMID:
9932816
36.

Changes in the liver protein pattern of female Wistar rats treated with the hypoglycemic agent SDZ PGU 693.

Arce A, Aicher L, Wahl D, Anderson NL, Meheus L, Raymackers J, Cordier A, Steiner S.

Life Sci. 1998;63(25):2243-50.

PMID:
9870710
37.

Cyclosporine A decreases the protein level of the calcium-binding protein calbindin-D 28kDa in rat kidney.

Steiner S, Aicher L, Raymackers J, Meheus L, Esquer-Blasco R, Anderson NL, Cordier A.

Biochem Pharmacol. 1996 Feb 9;51(3):253-8.

PMID:
8573191
38.

Induction of the adipose differentiation-related protein in liver of etomoxir-treated rats.

Steiner S, Wahl D, Mangold BL, Robison R, Raymackers J, Meheus L, Anderson NL, Cordier A.

Biochem Biophys Res Commun. 1996 Jan 26;218(3):777-82.

PMID:
8579590
39.

Evaluation of recombinant RO/SSA, La/SSB, Sm and U1 RNP autoantigens in clinical diagnosis.

Meheus L, Union A.

J Clin Lab Anal. 1996;10(1):57-8. No abstract available.

PMID:
8926567
40.

An updated two-dimensional gel database of rat liver proteins useful in gene regulation and drug effect studies.

Anderson NL, Esquer-Blasco R, Hofmann JP, Meheus L, Raymackers J, Steiner S, Witzmann F, Anderson NG.

Electrophoresis. 1995 Oct;16(10):1977-81.

PMID:
8586073
42.

Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope protein.

Hertogs K, Leenders WP, Depla E, De Bruin WC, Meheus L, Raymackers J, Moshage H, Yap SH.

Virology. 1993 Dec;197(2):549-57.

PMID:
8249278
43.

Identification by microsequencing of lipopolysaccharide-induced proteins secreted by mouse macrophages.

Meheus LA, Fransen LM, Raymackers JG, Blockx HA, Van Beeumen JJ, Van Bun SM, Van de Voorde A.

J Immunol. 1993 Aug 1;151(3):1535-47.

PMID:
8335946
44.

Peptide mapping and microsequencing of proteins separated by SDS-PAGE after limited in situ acid hydrolysis.

Vanfleteren JR, Raymackers JG, Van Bun SM, Meheus LA.

Biotechniques. 1992 Apr;12(4):550-2, 554, 556-7.

PMID:
1323976
45.

Age-specific nuclear proteins in the nematode worm Caenorhabditis elegans.

Meheus LA, Van Beeumen JJ, Coomans AV, Vanfleteren JR.

Biochem J. 1987 Jul 1;245(1):257-61.

46.

Supplemental Content

Loading ...
Support Center